Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alogliptin α injection to prevent neutropenia in biweekly chemotherapy for colorectal/pancreatic cancer
ChiCTR2500107802Phase 3Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2025
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of efbemalenograstim alfa in colorectal adenocarcinoma and pancreatic adenocarcinoma (PDAC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Incidence of grade ≥3 ANC reduction in first cycle of chemotherapy. Started Aug 2025; status: recruiting.
02
Drugs
efbemalenograstim alfa
03
Conditions
colorectal adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500107802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107802.